speb/financial-data huggingface dataset:
LYPSAGEMS.NS income_statement (annual, 2022-03-31) — Selling And Marketing Expense: 0.00
LYPSAGEMS.NS income_statement (annual, 2022-03-31) — Selling General And Administration: 1958000.00
LYPSAGEMS.NS balance_sheet (annual, 2022-03-31) — Share Issued: 29484000.00
LYPSAGEMS.NS cash_flow (annual, 2022-03-31) — Short Term Debt Payments: -72193000.00
LYPSAGEMS.NS income_statement (annual, 2022-03-31) — Special Income Charges: 1813000.00
LYPSAGEMS.NS balance_sheet (annual, 2022-03-31) — Stockholders Equity: 1021327000.00
LYPSAGEMS.NS balance_sheet (annual, 2022-03-31) — Tangible Book Value: 1021327000.00
LYPSAGEMS.NS income_statement (annual, 2022-03-31) — Tax Effect Of Unusual Items: 444907.98
LYPSAGEMS.NS income_statement (annual, 2022-03-31) — Tax Provision: -280000.00
LYPSAGEMS.NS income_statement (annual, 2022-03-31) — Tax Rate For Calcs: 0.25
LYPSAGEMS.NS balance_sheet (annual, 2022-03-31) — Total Assets: 2789057000.00
LYPSAGEMS.NS balance_sheet (annual, 2022-03-31) — Total Capitalization: 1021327000.00
LYPSAGEMS.NS balance_sheet (annual, 2022-03-31) — Total Debt: 133853000.00
LYPSAGEMS.NS balance_sheet (annual, 2022-03-31) — Total Equity Gross Minority Interest: 1021327000.00
LYPSAGEMS.NS income_statement (annual, 2022-03-31) — Total Expenses: 143194000.00
LYPSAGEMS.NS balance_sheet (annual, 2022-03-31) — Total Liabilities Net Minority Interest: 1767730000.00
LYPSAGEMS.NS balance_sheet (annual, 2022-03-31) — Total Non Current Assets: 36005000.00
LYPSAGEMS.NS balance_sheet (annual, 2022-03-31) — Total Non Current Liabilities Net Minority Interest: 2934000.00
LYPSAGEMS.NS balance_sheet (annual, 2022-03-31) — Total Tax Payable: 0.00
LYPSAGEMS.NS income_statement (annual, 2022-03-31) — Total Unusual Items: 1813000.00
LYPSAGEMS.NS income_statement (annual, 2022-03-31) — Total Unusual Items Excluding Goodwill: 1813000.00
LYPSAGEMS.NS balance_sheet (annual, 2022-03-31) — Trading Securities: 0.00
LYPSAGEMS.NS balance_sheet (annual, 2022-03-31) — Work In Process: 0.00
LYPSAGEMS.NS balance_sheet (annual, 2022-03-31) — Working Capital: 988257000.00
LYPSAGEMS.NS income_statement (annual, 2022-03-31) — Write Off: -1914000.00
LYPSAGEMS.NS income_statement (annual, 2023-03-31) — +Operating Expense: 444336000.00
LYPSAGEMS.NS income_statement (annual, 2023-03-31) — +Total Revenue: 131935000.00
LYPSAGEMS.NS balance_sheet (annual, 2023-03-31) — Accounts Payable: 480521000.00
LYPSAGEMS.NS balance_sheet (annual, 2023-03-31) — Accounts Receivable: 1151861000.00
LYPSAGEMS.NS balance_sheet (annual, 2023-03-31) — Accumulated Depreciation: -34408000.00
LYPSAGEMS.NS balance_sheet (annual, 2023-03-31) — Additional Paid In Capital: 59235000.00
LYPSAGEMS.NS balance_sheet (annual, 2023-03-31) — Available For Sale Securities: 749000.00
LYPSAGEMS.NS income_statement (annual, 2023-03-31) — Basic Average Shares: 29484000.00
LYPSAGEMS.NS income_statement (annual, 2023-03-31) — Basic EPS: -14.96
LYPSAGEMS.NS cash_flow (annual, 2023-03-31) — Beginning Cash Position: 5611000.00
LYPSAGEMS.NS balance_sheet (annual, 2023-03-31) — Buildings And Improvements: 14712000.00
LYPSAGEMS.NS balance_sheet (annual, 2023-03-31) — Capital Stock: 294840000.00
LYPSAGEMS.NS balance_sheet (annual, 2023-03-31) — Cash And Cash Equivalents: 4729000.00
LYPSAGEMS.NS balance_sheet (annual, 2023-03-31) — Cash Cash Equivalents And Short Term Investments: 4729000.00
LYPSAGEMS.NS balance_sheet (annual, 2023-03-31) — Cash Equivalents: 0.00
LYPSAGEMS.NS balance_sheet (annual, 2023-03-31) — Cash Financial: 4729000.00
LYPSAGEMS.NS cash_flow (annual, 2023-03-31) — Change In Inventory: 7586000.00
LYPSAGEMS.NS cash_flow (annual, 2023-03-31) — Change In Other Current Assets: 1319000.00
LYPSAGEMS.NS cash_flow (annual, 2023-03-31) — Change In Other Current Liabilities: -4492000.00
LYPSAGEMS.NS cash_flow (annual, 2023-03-31) — Change In Payable: -30649000.00
LYPSAGEMS.NS cash_flow (annual, 2023-03-31) — Change In Receivables: 96263000.00
LYPSAGEMS.NS cash_flow (annual, 2023-03-31) — Change In Working Capital: 70027000.00
LYPSAGEMS.NS cash_flow (annual, 2023-03-31) — Changes In Cash: -1086000.00
LYPSAGEMS.NS balance_sheet (annual, 2023-03-31) — Common Stock: 294840000.00
LYPSAGEMS.NS balance_sheet (annual, 2023-03-31) — Common Stock Equity: 639333000.00
LYPSAGEMS.NS balance_sheet (annual, 2023-03-31) — Construction In Progress: 0.00
LYPSAGEMS.NS income_statement (annual, 2023-03-31) — Cost Of Revenue: 128535000.00
LYPSAGEMS.NS balance_sheet (annual, 2023-03-31) — Current Assets: 1161633000.00
LYPSAGEMS.NS balance_sheet (annual, 2023-03-31) — Current Debt: 60001000.00
LYPSAGEMS.NS balance_sheet (annual, 2023-03-31) — Current Debt And Capital Lease Obligation: 60001000.00
LYPSAGEMS.NS balance_sheet (annual, 2023-03-31) — Current Deferred Assets: 0.00
LYPSAGEMS.NS balance_sheet (annual, 2023-03-31) — Current Liabilities: 551297000.00
LYPSAGEMS.NS balance_sheet (annual, 2023-03-31) — Current Provisions: 366000.00
LYPSAGEMS.NS cash_flow (annual, 2023-03-31) — Deferred Tax: -36000.00
LYPSAGEMS.NS cash_flow (annual, 2023-03-31) — Depreciation: 2719000.00
LYPSAGEMS.NS cash_flow (annual, 2023-03-31) — Depreciation And Amortization: 2719000.00
LYPSAGEMS.NS income_statement (annual, 2023-03-31) — Depreciation And Amortization In Income Statement: 2719000.00
LYPSAGEMS.NS income_statement (annual, 2023-03-31) — Depreciation Income Statement: 2719000.00
LYPSAGEMS.NS income_statement (annual, 2023-03-31) — Diluted Average Shares: 29484000.00
LYPSAGEMS.NS income_statement (annual, 2023-03-31) — Diluted EPS: -14.96
LYPSAGEMS.NS income_statement (annual, 2023-03-31) — Diluted NI Availto Com Stockholders: -440972000.00
LYPSAGEMS.NS balance_sheet (annual, 2023-03-31) — Dividends Payable: 4336000.00
LYPSAGEMS.NS income_statement (annual, 2023-03-31) — EBIT: -440936000.00
LYPSAGEMS.NS income_statement (annual, 2023-03-31) — EBITDA: -438217000.00
LYPSAGEMS.NS cash_flow (annual, 2023-03-31) — End Cash Position: 4525000.00
LYPSAGEMS.NS cash_flow (annual, 2023-03-31) — Financing Cash Flow: -73851000.00
LYPSAGEMS.NS balance_sheet (annual, 2023-03-31) — Finished Goods: 4484000.00
LYPSAGEMS.NS cash_flow (annual, 2023-03-31) — Free Cash Flow: 72765000.00
LYPSAGEMS.NS cash_flow (annual, 2023-03-31) — Gain Loss On Sale Of PPE: 0.00
LYPSAGEMS.NS income_statement (annual, 2023-03-31) — General And Administrative Expense: 1930000.00
LYPSAGEMS.NS balance_sheet (annual, 2023-03-31) — Goodwill And Other Intangible Assets: 0.00
LYPSAGEMS.NS balance_sheet (annual, 2023-03-31) — Gross PPE: 65872000.00
LYPSAGEMS.NS income_statement (annual, 2023-03-31) — Gross Profit: 3400000.00
LYPSAGEMS.NS income_statement (annual, 2023-03-31) — Interest Expense: 0.00
LYPSAGEMS.NS income_statement (annual, 2023-03-31) — Interest Expense Non Operating: 0.00
LYPSAGEMS.NS income_statement (annual, 2023-03-31) — Interest Income: 0.00
LYPSAGEMS.NS income_statement (annual, 2023-03-31) — Interest Income Non Operating: 0.00
LYPSAGEMS.NS balance_sheet (annual, 2023-03-31) — Inventory: 5043000.00
LYPSAGEMS.NS balance_sheet (annual, 2023-03-31) — Invested Capital: 699334000.00
LYPSAGEMS.NS cash_flow (annual, 2023-03-31) — Investing Cash Flow: 0.00
LYPSAGEMS.NS balance_sheet (annual, 2023-03-31) — Investmentin Financial Assets: 0.00
LYPSAGEMS.NS balance_sheet (annual, 2023-03-31) — Land And Improvements: 5720000.00
LYPSAGEMS.NS balance_sheet (annual, 2023-03-31) — Long Term Debt: 0.00
LYPSAGEMS.NS balance_sheet (annual, 2023-03-31) — Long Term Debt And Capital Lease Obligation: 0.00
LYPSAGEMS.NS balance_sheet (annual, 2023-03-31) — Machinery Furniture Equipment: 44354000.00
LYPSAGEMS.NS balance_sheet (annual, 2023-03-31) — Net Debt: 55272000.00
LYPSAGEMS.NS income_statement (annual, 2023-03-31) — Net Income: -440972000.00
LYPSAGEMS.NS income_statement (annual, 2023-03-31) — Net Income Common Stockholders: -440972000.00
LYPSAGEMS.NS income_statement (annual, 2023-03-31) — Net Income Continuous Operations: -440972000.00
LYPSAGEMS.NS income_statement (annual, 2023-03-31) — Net Income Discontinuous Operations: 0.00
LYPSAGEMS.NS income_statement (annual, 2023-03-31) — Net Income From Continuing And Discontinued Operation: -440972000.00
LYPSAGEMS.NS income_statement (annual, 2023-03-31) — Net Income From Continuing Operation Net Minority Interest: -440972000.00
LYPSAGEMS.NS cash_flow (annual, 2023-03-31) — Net Income From Continuing Operations: 311000.00
LYPSAGEMS.NS income_statement (annual, 2023-03-31) — Net Income Including Noncontrolling Interests: -440972000.00
LYPSAGEMS.NS income_statement (annual, 2023-03-31) — Net Interest Income: 0.00
LYPSAGEMS.NS cash_flow (annual, 2023-03-31) — Net Issuance Payments Of Debt: -73851000.00
LYPSAGEMS.NS income_statement (annual, 2023-03-31) — Net Non Operating Interest Income Expense: 0.00
LYPSAGEMS.NS balance_sheet (annual, 2023-03-31) — Net PPE: 31464000.00
LYPSAGEMS.NS cash_flow (annual, 2023-03-31) — Net PPE Purchase And Sale: 0.00
LYPSAGEMS.NS cash_flow (annual, 2023-03-31) — Net Short Term Debt Issuance: -73851000.00
LYPSAGEMS.NS balance_sheet (annual, 2023-03-31) — Net Tangible Assets: 639333000.00
LYPSAGEMS.NS balance_sheet (annual, 2023-03-31) — Non Current Deferred Taxes Assets: 0.00
LYPSAGEMS.NS balance_sheet (annual, 2023-03-31) — Non Current Deferred Taxes Liabilities: 2971000.00
LYPSAGEMS.NS balance_sheet (annual, 2023-03-31) — Non Current Prepaid Assets: 282000.00
LYPSAGEMS.NS income_statement (annual, 2023-03-31) — Normalized EBITDA: -438217000.00
LYPSAGEMS.NS income_statement (annual, 2023-03-31) — Normalized Income: -440972000.00
LYPSAGEMS.NS cash_flow (annual, 2023-03-31) — Operating Cash Flow: 72765000.00
LYPSAGEMS.NS income_statement (annual, 2023-03-31) — Operating Income: -440936000.00
LYPSAGEMS.NS income_statement (annual, 2023-03-31) — Operating Revenue: 131935000.00
LYPSAGEMS.NS balance_sheet (annual, 2023-03-31) — Ordinary Shares Number: 29484000.00
LYPSAGEMS.NS balance_sheet (annual, 2023-03-31) — Other Current Assets: 483000.00
LYPSAGEMS.NS balance_sheet (annual, 2023-03-31) — Other Current Liabilities: 3000.00
LYPSAGEMS.NS balance_sheet (annual, 2023-03-31) — Other Equity Interest: 23275000.00
LYPSAGEMS.NS cash_flow (annual, 2023-03-31) — Other Non Cash Items: -256000.00
LYPSAGEMS.NS income_statement (annual, 2023-03-31) — Other Operating Expenses: 441461000.00
LYPSAGEMS.NS balance_sheet (annual, 2023-03-31) — Other Payable: 6436000.00
LYPSAGEMS.NS balance_sheet (annual, 2023-03-31) — Other Properties: 1086000.00
LYPSAGEMS.NS balance_sheet (annual, 2023-03-31) — Other Short Term Investments: 4480000.00
LYPSAGEMS.NS income_statement (annual, 2023-03-31) — Otherunder Preferred Stock Dividend: 0.00
LYPSAGEMS.NS balance_sheet (annual, 2023-03-31) — Payables: 491293000.00
LYPSAGEMS.NS balance_sheet (annual, 2023-03-31) — Prepaid Assets: 0.00
LYPSAGEMS.NS income_statement (annual, 2023-03-31) — Pretax Income: -440936000.00
LYPSAGEMS.NS balance_sheet (annual, 2023-03-31) — Properties: 0.00
LYPSAGEMS.NS cash_flow (annual, 2023-03-31) — Provisionand Write Offof Assets: 0.00
LYPSAGEMS.NS balance_sheet (annual, 2023-03-31) — Raw Materials: 559000.00
LYPSAGEMS.NS income_statement (annual, 2023-03-31) — Reconciled Cost Of Revenue: 128535000.00
LYPSAGEMS.NS income_statement (annual, 2023-03-31) — Reconciled Depreciation: 2719000.00
LYPSAGEMS.NS income_statement (annual, 2023-03-31) — Rent And Landing Fees: 0.00
LYPSAGEMS.NS income_statement (annual, 2023-03-31) — Rent Expense Supplemental: 0.00
LYPSAGEMS.NS cash_flow (annual, 2023-03-31) — Repayment Of Debt: -73851000.00
LYPSAGEMS.NS balance_sheet (annual, 2023-03-31) — Retained Earnings: 285258000.00
LYPSAGEMS.NS cash_flow (annual, 2023-03-31) — Sale Of PPE: 0.00
LYPSAGEMS.NS income_statement (annual, 2023-03-31) — Selling And Marketing Expense: 0.00
LYPSAGEMS.NS income_statement (annual, 2023-03-31) — Selling General And Administration: 1930000.00
LYPSAGEMS.NS balance_sheet (annual, 2023-03-31) — Share Issued: 29484000.00
LYPSAGEMS.NS cash_flow (annual, 2023-03-31) — Short Term Debt Payments: -73851000.00
LYPSAGEMS.NS income_statement (annual, 2023-03-31) — Special Income Charges: -439452000.00
LYPSAGEMS.NS balance_sheet (annual, 2023-03-31) — Stockholders Equity: 639333000.00
LYPSAGEMS.NS balance_sheet (annual, 2023-03-31) — Tangible Book Value: 639333000.00
LYPSAGEMS.NS income_statement (annual, 2023-03-31) — Tax Effect Of Unusual Items: 0.00
LYPSAGEMS.NS income_statement (annual, 2023-03-31) — Tax Provision: 36000.00
LYPSAGEMS.NS income_statement (annual, 2023-03-31) — Tax Rate For Calcs: 0.30
LYPSAGEMS.NS balance_sheet (annual, 2023-03-31) — Total Assets: 1193601000.00
LYPSAGEMS.NS balance_sheet (annual, 2023-03-31) — Total Capitalization: 639333000.00
LYPSAGEMS.NS balance_sheet (annual, 2023-03-31) — Total Debt: 60001000.00
LYPSAGEMS.NS balance_sheet (annual, 2023-03-31) — Total Equity Gross Minority Interest: 639333000.00
LYPSAGEMS.NS income_statement (annual, 2023-03-31) — Total Expenses: 572871000.00
LYPSAGEMS.NS balance_sheet (annual, 2023-03-31) — Total Liabilities Net Minority Interest: 554268000.00
LYPSAGEMS.NS balance_sheet (annual, 2023-03-31) — Total Non Current Assets: 31946000.00
LYPSAGEMS.NS balance_sheet (annual, 2023-03-31) — Total Non Current Liabilities Net Minority Interest: 2971000.00
LYPSAGEMS.NS balance_sheet (annual, 2023-03-31) — Total Tax Payable: 0.00
LYPSAGEMS.NS income_statement (annual, 2023-03-31) — Total Unusual Items: 0.00
LYPSAGEMS.NS income_statement (annual, 2023-03-31) — Total Unusual Items Excluding Goodwill: 0.00
LYPSAGEMS.NS balance_sheet (annual, 2023-03-31) — Trading Securities: 0.00
LYPSAGEMS.NS balance_sheet (annual, 2023-03-31) — Work In Process: 0.00
LYPSAGEMS.NS balance_sheet (annual, 2023-03-31) — Working Capital: 610336000.00
LYPSAGEMS.NS income_statement (annual, 2023-03-31) — Write Off: 439452000.00
LYPSAGEMS.NS income_statement (annual, 2024-03-31) — +Operating Expense: 4516000.00
LYPSAGEMS.NS income_statement (annual, 2024-03-31) — +Total Revenue: 94854000.00
LYPSAGEMS.NS balance_sheet (annual, 2024-03-31) — Accounts Payable: 368297000.00
LYPSAGEMS.NS balance_sheet (annual, 2024-03-31) — Accounts Receivable: 712395000.00
LYPSAGEMS.NS balance_sheet (annual, 2024-03-31) — Accumulated Depreciation: -36767000.00
LYPSAGEMS.NS balance_sheet (annual, 2024-03-31) — Additional Paid In Capital: 0.00
LYPSAGEMS.NS income_statement (annual, 2024-03-31) — Basic Average Shares: 29484000.00
LYPSAGEMS.NS income_statement (annual, 2024-03-31) — Basic EPS: -11.09
LYPSAGEMS.NS cash_flow (annual, 2024-03-31) — Beginning Cash Position: 4729000.00
LYPSAGEMS.NS balance_sheet (annual, 2024-03-31) — Buildings And Improvements: 14712000.00
LYPSAGEMS.NS balance_sheet (annual, 2024-03-31) — Capital Stock: 294840000.00
LYPSAGEMS.NS balance_sheet (annual, 2024-03-31) — Cash And Cash Equivalents: 4465000.00
LYPSAGEMS.NS balance_sheet (annual, 2024-03-31) — Cash Cash Equivalents And Short Term Investments: 4465000.00
LYPSAGEMS.NS balance_sheet (annual, 2024-03-31) — Cash Equivalents: 0.00
LYPSAGEMS.NS balance_sheet (annual, 2024-03-31) — Cash Financial: 4465000.00
LYPSAGEMS.NS cash_flow (annual, 2024-03-31) — Change In Inventory: -3510000.00
LYPSAGEMS.NS cash_flow (annual, 2024-03-31) — Change In Other Current Assets: -11000.00
LYPSAGEMS.NS cash_flow (annual, 2024-03-31) — Change In Other Current Liabilities: -5835000.00
LYPSAGEMS.NS cash_flow (annual, 2024-03-31) — Change In Payable: -111145000.00
LYPSAGEMS.NS cash_flow (annual, 2024-03-31) — Change In Receivables: 112336000.00
LYPSAGEMS.NS cash_flow (annual, 2024-03-31) — Change In Working Capital: -8165000.00
LYPSAGEMS.NS cash_flow (annual, 2024-03-31) — Changes In Cash: -264000.00
LYPSAGEMS.NS balance_sheet (annual, 2024-03-31) — Common Stock: 294840000.00
LYPSAGEMS.NS balance_sheet (annual, 2024-03-31) — Common Stock Equity: 317055000.00
LYPSAGEMS.NS balance_sheet (annual, 2024-03-31) — Construction In Progress: 0.00
LYPSAGEMS.NS income_statement (annual, 2024-03-31) — Cost Of Revenue: 90987000.00
LYPSAGEMS.NS balance_sheet (annual, 2024-03-31) — Current Assets: 725412000.00
LYPSAGEMS.NS balance_sheet (annual, 2024-03-31) — Current Debt: 61358000.00
LYPSAGEMS.NS balance_sheet (annual, 2024-03-31) — Current Debt And Capital Lease Obligation: 61358000.00
LYPSAGEMS.NS balance_sheet (annual, 2024-03-31) — Current Deferred Assets: 0.00
LYPSAGEMS.NS balance_sheet (annual, 2024-03-31) — Current Liabilities: 434594000.00
LYPSAGEMS.NS balance_sheet (annual, 2024-03-31) — Current Provisions: 4573000.00
LYPSAGEMS.NS cash_flow (annual, 2024-03-31) — Deferred Tax: -415000.00
LYPSAGEMS.NS cash_flow (annual, 2024-03-31) — Depreciation: 2358000.00
LYPSAGEMS.NS cash_flow (annual, 2024-03-31) — Depreciation And Amortization: 2358000.00
LYPSAGEMS.NS income_statement (annual, 2024-03-31) — Depreciation And Amortization In Income Statement: 2358000.00
LYPSAGEMS.NS income_statement (annual, 2024-03-31) — Depreciation Income Statement: 2358000.00
LYPSAGEMS.NS income_statement (annual, 2024-03-31) — Diluted Average Shares: 29484000.00
LYPSAGEMS.NS income_statement (annual, 2024-03-31) — Diluted EPS: -11.09
LYPSAGEMS.NS income_statement (annual, 2024-03-31) — Diluted NI Availto Com Stockholders: -327117000.00
LYPSAGEMS.NS balance_sheet (annual, 2024-03-31) — Dividends Payable: 4336000.00
LYPSAGEMS.NS income_statement (annual, 2024-03-31) — EBIT: -326701000.00
LYPSAGEMS.NS income_statement (annual, 2024-03-31) — EBITDA: -324343000.00
LYPSAGEMS.NS cash_flow (annual, 2024-03-31) — End Cash Position: 4465000.00
LYPSAGEMS.NS cash_flow (annual, 2024-03-31) — Financing Cash Flow: 1356000.00
LYPSAGEMS.NS balance_sheet (annual, 2024-03-31) — Finished Goods: 5714000.00
LYPSAGEMS.NS cash_flow (annual, 2024-03-31) — Free Cash Flow: -1620000.00
LYPSAGEMS.NS cash_flow (annual, 2024-03-31) — Gain Loss On Sale Of PPE: 0.00
LYPSAGEMS.NS income_statement (annual, 2024-03-31) — General And Administrative Expense: 1942000.00
LYPSAGEMS.NS balance_sheet (annual, 2024-03-31) — Goodwill And Other Intangible Assets: 0.00
LYPSAGEMS.NS balance_sheet (annual, 2024-03-31) — Gross PPE: 65872000.00
LYPSAGEMS.NS income_statement (annual, 2024-03-31) — Gross Profit: 3867000.00
LYPSAGEMS.NS income_statement (annual, 2024-03-31) — Interest Expense: 1000.00
LYPSAGEMS.NS income_statement (annual, 2024-03-31) — Interest Expense Non Operating: 1000.00
LYPSAGEMS.NS income_statement (annual, 2024-03-31) — Interest Income: 0.00
LYPSAGEMS.NS income_statement (annual, 2024-03-31) — Interest Income Non Operating: 0.00
LYPSAGEMS.NS balance_sheet (annual, 2024-03-31) — Inventory: 8552000.00
LYPSAGEMS.NS balance_sheet (annual, 2024-03-31) — Invested Capital: 378413000.00
LYPSAGEMS.NS cash_flow (annual, 2024-03-31) — Investing Cash Flow: 0.00
LYPSAGEMS.NS balance_sheet (annual, 2024-03-31) — Investmentin Financial Assets: 0.00
LYPSAGEMS.NS cash_flow (annual, 2024-03-31) — Issuance Of Debt: 1356000.00
LYPSAGEMS.NS balance_sheet (annual, 2024-03-31) — Land And Improvements: 5720000.00
LYPSAGEMS.NS balance_sheet (annual, 2024-03-31) — Machinery Furniture Equipment: 44354000.00
LYPSAGEMS.NS balance_sheet (annual, 2024-03-31) — Net Debt: 56893000.00
LYPSAGEMS.NS income_statement (annual, 2024-03-31) — Net Income: -327117000.00
LYPSAGEMS.NS income_statement (annual, 2024-03-31) — Net Income Common Stockholders: -327117000.00
LYPSAGEMS.NS income_statement (annual, 2024-03-31) — Net Income Continuous Operations: -327117000.00
LYPSAGEMS.NS income_statement (annual, 2024-03-31) — Net Income Discontinuous Operations: 0.00
LYPSAGEMS.NS income_statement (annual, 2024-03-31) — Net Income From Continuing And Discontinued Operation: -327117000.00
LYPSAGEMS.NS income_statement (annual, 2024-03-31) — Net Income From Continuing Operation Net Minority Interest: -327117000.00
LYPSAGEMS.NS cash_flow (annual, 2024-03-31) — Net Income From Continuing Operations: -326702000.00
LYPSAGEMS.NS income_statement (annual, 2024-03-31) — Net Income Including Noncontrolling Interests: -327117000.00
LYPSAGEMS.NS income_statement (annual, 2024-03-31) — Net Interest Income: -1000.00
LYPSAGEMS.NS cash_flow (annual, 2024-03-31) — Net Issuance Payments Of Debt: 1356000.00
LYPSAGEMS.NS income_statement (annual, 2024-03-31) — Net Non Operating Interest Income Expense: -1000.00
LYPSAGEMS.NS balance_sheet (annual, 2024-03-31) — Net PPE: 29105000.00
LYPSAGEMS.NS cash_flow (annual, 2024-03-31) — Net PPE Purchase And Sale: 0.00
LYPSAGEMS.NS cash_flow (annual, 2024-03-31) — Net Short Term Debt Issuance: 1356000.00
LYPSAGEMS.NS balance_sheet (annual, 2024-03-31) — Net Tangible Assets: 317055000.00
LYPSAGEMS.NS balance_sheet (annual, 2024-03-31) — Non Current Deferred Taxes Assets: 0.00
LYPSAGEMS.NS balance_sheet (annual, 2024-03-31) — Non Current Deferred Taxes Liabilities: 3386000.00
LYPSAGEMS.NS balance_sheet (annual, 2024-03-31) — Non Current Prepaid Assets: 315000.00
LYPSAGEMS.NS income_statement (annual, 2024-03-31) — Normalized EBITDA: 1708000.00
LYPSAGEMS.NS income_statement (annual, 2024-03-31) — Normalized Income: -98881300.00
LYPSAGEMS.NS cash_flow (annual, 2024-03-31) — Operating Cash Flow: -1620000.00
LYPSAGEMS.NS income_statement (annual, 2024-03-31) — Operating Income: -649000.00
LYPSAGEMS.NS income_statement (annual, 2024-03-31) — Operating Revenue: 94854000.00
LYPSAGEMS.NS balance_sheet (annual, 2024-03-31) — Ordinary Shares Number: 29484000.00
LYPSAGEMS.NS balance_sheet (annual, 2024-03-31) — Other Current Assets: 515000.00
LYPSAGEMS.NS balance_sheet (annual, 2024-03-31) — Other Current Liabilities: 3000.00
LYPSAGEMS.NS balance_sheet (annual, 2024-03-31) — Other Equity Interest: 22215000.00
LYPSAGEMS.NS income_statement (annual, 2024-03-31) — Other Operating Expenses: 48000.00
LYPSAGEMS.NS balance_sheet (annual, 2024-03-31) — Other Payable: 600000.00
LYPSAGEMS.NS balance_sheet (annual, 2024-03-31) — Other Properties: 1086000.00
LYPSAGEMS.NS balance_sheet (annual, 2024-03-31) — Other Short Term Investments: 4433000.00
LYPSAGEMS.NS income_statement (annual, 2024-03-31) — Otherunder Preferred Stock Dividend: 0.00
LYPSAGEMS.NS balance_sheet (annual, 2024-03-31) — Payables: 373233000.00
LYPSAGEMS.NS balance_sheet (annual, 2024-03-31) — Prepaid Assets: 0.00
LYPSAGEMS.NS income_statement (annual, 2024-03-31) — Pretax Income: -326702000.00
LYPSAGEMS.NS balance_sheet (annual, 2024-03-31) — Properties: 0.00
LYPSAGEMS.NS cash_flow (annual, 2024-03-31) — Provisionand Write Offof Assets: 4174000.00
LYPSAGEMS.NS balance_sheet (annual, 2024-03-31) — Raw Materials: 2838000.00
LYPSAGEMS.NS income_statement (annual, 2024-03-31) — Reconciled Cost Of Revenue: 90987000.00
LYPSAGEMS.NS income_statement (annual, 2024-03-31) — Reconciled Depreciation: 2358000.00
LYPSAGEMS.NS income_statement (annual, 2024-03-31) — Rent And Landing Fees: 0.00
LYPSAGEMS.NS income_statement (annual, 2024-03-31) — Rent Expense Supplemental: 0.00
LYPSAGEMS.NS balance_sheet (annual, 2024-03-31) — Retained Earnings: 17376000.00
LYPSAGEMS.NS cash_flow (annual, 2024-03-31) — Sale Of PPE: 0.00
LYPSAGEMS.NS income_statement (annual, 2024-03-31) — Selling And Marketing Expense: 0.00
LYPSAGEMS.NS income_statement (annual, 2024-03-31) — Selling General And Administration: 1942000.00
LYPSAGEMS.NS balance_sheet (annual, 2024-03-31) — Share Issued: 29484000.00
LYPSAGEMS.NS cash_flow (annual, 2024-03-31) — Short Term Debt Issuance: 1356000.00
LYPSAGEMS.NS income_statement (annual, 2024-03-31) — Special Income Charges: -326051000.00
LYPSAGEMS.NS balance_sheet (annual, 2024-03-31) — Stockholders Equity: 317055000.00
LYPSAGEMS.NS balance_sheet (annual, 2024-03-31) — Tangible Book Value: 317055000.00
LYPSAGEMS.NS income_statement (annual, 2024-03-31) — Tax Effect Of Unusual Items: -97815300.00
LYPSAGEMS.NS income_statement (annual, 2024-03-31) — Tax Provision: 415000.00
LYPSAGEMS.NS income_statement (annual, 2024-03-31) — Tax Rate For Calcs: 0.30
LYPSAGEMS.NS balance_sheet (annual, 2024-03-31) — Total Assets: 755035000.00
LYPSAGEMS.NS balance_sheet (annual, 2024-03-31) — Total Capitalization: 317055000.00
LYPSAGEMS.NS balance_sheet (annual, 2024-03-31) — Total Debt: 61358000.00
LYPSAGEMS.NS balance_sheet (annual, 2024-03-31) — Total Equity Gross Minority Interest: 317055000.00
LYPSAGEMS.NS income_statement (annual, 2024-03-31) — Total Expenses: 95503000.00
LYPSAGEMS.NS balance_sheet (annual, 2024-03-31) — Total Liabilities Net Minority Interest: 437980000.00
LYPSAGEMS.NS balance_sheet (annual, 2024-03-31) — Total Non Current Assets: 29620000.00
LYPSAGEMS.NS balance_sheet (annual, 2024-03-31) — Total Non Current Liabilities Net Minority Interest: 3386000.00
LYPSAGEMS.NS balance_sheet (annual, 2024-03-31) — Total Tax Payable: 0.00
LYPSAGEMS.NS income_statement (annual, 2024-03-31) — Total Unusual Items: -326051000.00
LYPSAGEMS.NS income_statement (annual, 2024-03-31) — Total Unusual Items Excluding Goodwill: -326051000.00
LYPSAGEMS.NS balance_sheet (annual, 2024-03-31) — Work In Process: 0.00
LYPSAGEMS.NS balance_sheet (annual, 2024-03-31) — Working Capital: 290818000.00
LYPSAGEMS.NS income_statement (annual, 2024-03-31) — Write Off: 326051000.00
LYPSAGEMS.NS income_statement (quarterly, 2024-09-30) — +Operating Expense: 813000.00
LYPSAGEMS.NS income_statement (quarterly, 2024-09-30) — +Total Revenue: 27593000.00
LYPSAGEMS.NS balance_sheet (quarterly, 2024-09-30) — Accounts Payable: 350849000.00
LYPSAGEMS.NS balance_sheet (quarterly, 2024-09-30) — Accounts Receivable: 714395000.00
LYPSAGEMS.NS income_statement (quarterly, 2024-09-30) — Basic Average Shares: 29484000.00
LYPSAGEMS.NS income_statement (quarterly, 2024-09-30) — Basic EPS: 0.00
LYPSAGEMS.NS balance_sheet (quarterly, 2024-09-30) — Capital Stock: 294840000.00
LYPSAGEMS.NS balance_sheet (quarterly, 2024-09-30) — Cash And Cash Equivalents: 32000.00
LYPSAGEMS.NS balance_sheet (quarterly, 2024-09-30) — Cash Cash Equivalents And Short Term Investments: 4458000.00
LYPSAGEMS.NS balance_sheet (quarterly, 2024-09-30) — Common Stock: 294840000.00
LYPSAGEMS.NS balance_sheet (quarterly, 2024-09-30) — Common Stock Equity: 317943000.00
LYPSAGEMS.NS balance_sheet (quarterly, 2024-09-30) — Construction In Progress: 0.00
LYPSAGEMS.NS income_statement (quarterly, 2024-09-30) — Cost Of Revenue: 26635000.00
LYPSAGEMS.NS balance_sheet (quarterly, 2024-09-30) — Current Assets: 740083000.00
LYPSAGEMS.NS balance_sheet (quarterly, 2024-09-30) — Current Liabilities: 446772000.00
LYPSAGEMS.NS balance_sheet (quarterly, 2024-09-30) — Current Provisions: 4226000.00
LYPSAGEMS.NS income_statement (quarterly, 2024-09-30) — Depreciation And Amortization In Income Statement: 545000.00
LYPSAGEMS.NS income_statement (quarterly, 2024-09-30) — Depreciation Income Statement: 545000.00
LYPSAGEMS.NS income_statement (quarterly, 2024-09-30) — Diluted Average Shares: 29484000.00
LYPSAGEMS.NS income_statement (quarterly, 2024-09-30) — Diluted EPS: 0.00
LYPSAGEMS.NS income_statement (quarterly, 2024-09-30) — Diluted NI Availto Com Stockholders: 145000.00
LYPSAGEMS.NS income_statement (quarterly, 2024-09-30) — EBIT: 145000.00
LYPSAGEMS.NS income_statement (quarterly, 2024-09-30) — EBITDA: 690000.00
LYPSAGEMS.NS balance_sheet (quarterly, 2024-09-30) — Goodwill And Other Intangible Assets: 0.00
LYPSAGEMS.NS balance_sheet (quarterly, 2024-09-30) — Gross PPE: 28018000.00
LYPSAGEMS.NS income_statement (quarterly, 2024-09-30) — Gross Profit: 958000.00
LYPSAGEMS.NS income_statement (quarterly, 2024-09-30) — Interest Expense: 0.00
LYPSAGEMS.NS income_statement (quarterly, 2024-09-30) — Interest Expense Non Operating: 0.00
LYPSAGEMS.NS balance_sheet (quarterly, 2024-09-30) — Inventory: 20334000.00
LYPSAGEMS.NS balance_sheet (quarterly, 2024-09-30) — Invested Capital: 317943000.00
LYPSAGEMS.NS balance_sheet (quarterly, 2024-09-30) — Investmentin Financial Assets: 0.00
LYPSAGEMS.NS income_statement (quarterly, 2024-09-30) — Net Income: 145000.00
LYPSAGEMS.NS income_statement (quarterly, 2024-09-30) — Net Income Common Stockholders: 145000.00
LYPSAGEMS.NS income_statement (quarterly, 2024-09-30) — Net Income Continuous Operations: 145000.00
LYPSAGEMS.NS income_statement (quarterly, 2024-09-30) — Net Income From Continuing And Discontinued Operation: 145000.00
LYPSAGEMS.NS income_statement (quarterly, 2024-09-30) — Net Income From Continuing Operation Net Minority Interest: 145000.00
LYPSAGEMS.NS income_statement (quarterly, 2024-09-30) — Net Income Including Noncontrolling Interests: 145000.00
LYPSAGEMS.NS income_statement (quarterly, 2024-09-30) — Net Interest Income: 0.00
LYPSAGEMS.NS income_statement (quarterly, 2024-09-30) — Net Non Operating Interest Income Expense: 0.00
LYPSAGEMS.NS balance_sheet (quarterly, 2024-09-30) — Net PPE: 28018000.00
LYPSAGEMS.NS balance_sheet (quarterly, 2024-09-30) — Net Tangible Assets: 317943000.00
LYPSAGEMS.NS balance_sheet (quarterly, 2024-09-30) — Non Current Deferred Taxes Liabilities: 3386000.00
LYPSAGEMS.NS income_statement (quarterly, 2024-09-30) — Normalized EBITDA: 690000.00
LYPSAGEMS.NS income_statement (quarterly, 2024-09-30) — Normalized Income: 145000.00
LYPSAGEMS.NS income_statement (quarterly, 2024-09-30) — Operating Income: 145000.00
LYPSAGEMS.NS income_statement (quarterly, 2024-09-30) — Operating Revenue: 27593000.00
LYPSAGEMS.NS balance_sheet (quarterly, 2024-09-30) — Ordinary Shares Number: 29484000.00
LYPSAGEMS.NS balance_sheet (quarterly, 2024-09-30) — Other Current Assets: 896000.00
LYPSAGEMS.NS balance_sheet (quarterly, 2024-09-30) — Other Current Liabilities: 366000.00
LYPSAGEMS.NS balance_sheet (quarterly, 2024-09-30) — Other Equity Interest: 23103000.00
LYPSAGEMS.NS income_statement (quarterly, 2024-09-30) — Other Operating Expenses: 226000.00
LYPSAGEMS.NS balance_sheet (quarterly, 2024-09-30) — Other Properties: 28018000.00
LYPSAGEMS.NS balance_sheet (quarterly, 2024-09-30) — Other Short Term Investments: 4426000.00
LYPSAGEMS.NS income_statement (quarterly, 2024-09-30) — Otherunder Preferred Stock Dividend: 0.00
LYPSAGEMS.NS balance_sheet (quarterly, 2024-09-30) — Payables: 350849000.00
LYPSAGEMS.NS income_statement (quarterly, 2024-09-30) — Pretax Income: 145000.00
LYPSAGEMS.NS income_statement (quarterly, 2024-09-30) — Reconciled Cost Of Revenue: 26635000.00
LYPSAGEMS.NS income_statement (quarterly, 2024-09-30) — Reconciled Depreciation: 545000.00
LYPSAGEMS.NS balance_sheet (quarterly, 2024-09-30) — Share Issued: 29484000.00
LYPSAGEMS.NS balance_sheet (quarterly, 2024-09-30) — Stockholders Equity: 317943000.00
LYPSAGEMS.NS balance_sheet (quarterly, 2024-09-30) — Tangible Book Value: 317943000.00
LYPSAGEMS.NS income_statement (quarterly, 2024-09-30) — Tax Effect Of Unusual Items: 0.00
LYPSAGEMS.NS income_statement (quarterly, 2024-09-30) — Tax Provision: 0.00
LYPSAGEMS.NS income_statement (quarterly, 2024-09-30) — Tax Rate For Calcs: 0.00
LYPSAGEMS.NS balance_sheet (quarterly, 2024-09-30) — Total Assets: 768101000.00
LYPSAGEMS.NS balance_sheet (quarterly, 2024-09-30) — Total Capitalization: 317943000.00
LYPSAGEMS.NS balance_sheet (quarterly, 2024-09-30) — Total Equity Gross Minority Interest: 317943000.00
LYPSAGEMS.NS income_statement (quarterly, 2024-09-30) — Total Expenses: 27448000.00
LYPSAGEMS.NS balance_sheet (quarterly, 2024-09-30) — Total Liabilities Net Minority Interest: 450158000.00
LYPSAGEMS.NS balance_sheet (quarterly, 2024-09-30) — Total Non Current Assets: 28018000.00
LYPSAGEMS.NS balance_sheet (quarterly, 2024-09-30) — Total Non Current Liabilities Net Minority Interest: 3386000.00
LYPSAGEMS.NS balance_sheet (quarterly, 2024-09-30) — Working Capital: 293311000.00
LYPSAGEMS.NS income_statement (quarterly, 2024-12-31) — +Operating Expense: 816000.00
LYPSAGEMS.NS income_statement (quarterly, 2024-12-31) — +Total Revenue: 59332000.00
LYPSAGEMS.NS income_statement (quarterly, 2024-12-31) — Basic Average Shares: 29484000.00
LYPSAGEMS.NS income_statement (quarterly, 2024-12-31) — Basic EPS: 0.00
LYPSAGEMS.NS income_statement (quarterly, 2024-12-31) — Cost Of Revenue: 58369000.00
LYPSAGEMS.NS income_statement (quarterly, 2024-12-31) — Depreciation And Amortization In Income Statement: 537000.00
LYPSAGEMS.NS income_statement (quarterly, 2024-12-31) — Depreciation Income Statement: 537000.00
LYPSAGEMS.NS income_statement (quarterly, 2024-12-31) — Diluted Average Shares: 29484000.00
LYPSAGEMS.NS income_statement (quarterly, 2024-12-31) — Diluted EPS: 0.00
LYPSAGEMS.NS income_statement (quarterly, 2024-12-31) — Diluted NI Availto Com Stockholders: 147000.00
LYPSAGEMS.NS income_statement (quarterly, 2024-12-31) — EBIT: 147000.00
LYPSAGEMS.NS income_statement (quarterly, 2024-12-31) — EBITDA: 684000.00
LYPSAGEMS.NS income_statement (quarterly, 2024-12-31) — Gross Profit: 963000.00
LYPSAGEMS.NS income_statement (quarterly, 2024-12-31) — Interest Expense: 0.00
LYPSAGEMS.NS income_statement (quarterly, 2024-12-31) — Interest Expense Non Operating: 0.00
LYPSAGEMS.NS income_statement (quarterly, 2024-12-31) — Net Income: 147000.00
LYPSAGEMS.NS income_statement (quarterly, 2024-12-31) — Net Income Common Stockholders: 147000.00
LYPSAGEMS.NS income_statement (quarterly, 2024-12-31) — Net Income Continuous Operations: 147000.00
LYPSAGEMS.NS income_statement (quarterly, 2024-12-31) — Net Income From Continuing And Discontinued Operation: 147000.00
LYPSAGEMS.NS income_statement (quarterly, 2024-12-31) — Net Income From Continuing Operation Net Minority Interest: 147000.00
LYPSAGEMS.NS income_statement (quarterly, 2024-12-31) — Net Income Including Noncontrolling Interests: 147000.00
LYPSAGEMS.NS income_statement (quarterly, 2024-12-31) — Net Interest Income: 0.00
LYPSAGEMS.NS income_statement (quarterly, 2024-12-31) — Net Non Operating Interest Income Expense: 0.00
LYPSAGEMS.NS income_statement (quarterly, 2024-12-31) — Normalized EBITDA: 684000.00
LYPSAGEMS.NS income_statement (quarterly, 2024-12-31) — Normalized Income: 147000.00
LYPSAGEMS.NS income_statement (quarterly, 2024-12-31) — Operating Income: 147000.00
LYPSAGEMS.NS income_statement (quarterly, 2024-12-31) — Operating Revenue: 59332000.00
LYPSAGEMS.NS income_statement (quarterly, 2024-12-31) — Other Operating Expenses: 237000.00
LYPSAGEMS.NS income_statement (quarterly, 2024-12-31) — Otherunder Preferred Stock Dividend: 0.00
LYPSAGEMS.NS income_statement (quarterly, 2024-12-31) — Pretax Income: 147000.00
LYPSAGEMS.NS income_statement (quarterly, 2024-12-31) — Reconciled Cost Of Revenue: 58369000.00
LYPSAGEMS.NS income_statement (quarterly, 2024-12-31) — Reconciled Depreciation: 537000.00
LYPSAGEMS.NS income_statement (quarterly, 2024-12-31) — Tax Effect Of Unusual Items: 0.00
LYPSAGEMS.NS income_statement (quarterly, 2024-12-31) — Tax Provision: 0.00
LYPSAGEMS.NS income_statement (quarterly, 2024-12-31) — Tax Rate For Calcs: 0.00
LYPSAGEMS.NS income_statement (quarterly, 2024-12-31) — Total Expenses: 59185000.00
LYPSAGEMS.NS income_statement (annual, 2025-03-31) — +Operating Expense: 156097000.00
LYPSAGEMS.NS income_statement (quarterly, 2025-03-31) — +Operating Expense: 153593000.00
LYPSAGEMS.NS income_statement (annual, 2025-03-31) — +Total Revenue: 166876000.00
LYPSAGEMS.NS income_statement (quarterly, 2025-03-31) — +Total Revenue: 65774000.00
LYPSAGEMS.NS balance_sheet (annual, 2025-03-31) — Accounts Payable: 352003000.00
LYPSAGEMS.NS balance_sheet (quarterly, 2025-03-31) — Accounts Payable: 352003000.00
LYPSAGEMS.NS balance_sheet (annual, 2025-03-31) — Accounts Receivable: 600478000.00
LYPSAGEMS.NS balance_sheet (quarterly, 2025-03-31) — Accounts Receivable: 600478000.00
LYPSAGEMS.NS balance_sheet (annual, 2025-03-31) — Accumulated Depreciation: -38913000.00
LYPSAGEMS.NS balance_sheet (quarterly, 2025-03-31) — Accumulated Depreciation: -38913000.00
LYPSAGEMS.NS balance_sheet (annual, 2025-03-31) — Additional Paid In Capital: 0.00
LYPSAGEMS.NS balance_sheet (quarterly, 2025-03-31) — Additional Paid In Capital: 0.00
LYPSAGEMS.NS cash_flow (annual, 2025-03-31) — Amortization Cash Flow: 0.00
LYPSAGEMS.NS income_statement (annual, 2025-03-31) — Basic Average Shares: 29465437.00
LYPSAGEMS.NS income_statement (quarterly, 2025-03-31) — Basic Average Shares: 29494402.00
LYPSAGEMS.NS income_statement (annual, 2025-03-31) — Basic EPS: -5.15
LYPSAGEMS.NS income_statement (quarterly, 2025-03-31) — Basic EPS: -5.18
LYPSAGEMS.NS cash_flow (annual, 2025-03-31) — Beginning Cash Position: 4465000.00
LYPSAGEMS.NS balance_sheet (annual, 2025-03-31) — Buildings And Improvements: 14712000.00
LYPSAGEMS.NS balance_sheet (quarterly, 2025-03-31) — Buildings And Improvements: 14712000.00
LYPSAGEMS.NS balance_sheet (annual, 2025-03-31) — Capital Stock: 294840000.00
LYPSAGEMS.NS balance_sheet (quarterly, 2025-03-31) — Capital Stock: 294840000.00
LYPSAGEMS.NS balance_sheet (annual, 2025-03-31) — Cash And Cash Equivalents: 4472000.00
LYPSAGEMS.NS balance_sheet (quarterly, 2025-03-31) — Cash And Cash Equivalents: 4472000.00
LYPSAGEMS.NS balance_sheet (annual, 2025-03-31) — Cash Cash Equivalents And Short Term Investments: 4472000.00
LYPSAGEMS.NS balance_sheet (quarterly, 2025-03-31) — Cash Cash Equivalents And Short Term Investments: 4472000.00
LYPSAGEMS.NS balance_sheet (annual, 2025-03-31) — Cash Equivalents: 0.00
LYPSAGEMS.NS balance_sheet (quarterly, 2025-03-31) — Cash Equivalents: 0.00
LYPSAGEMS.NS balance_sheet (annual, 2025-03-31) — Cash Financial: 4472000.00
LYPSAGEMS.NS balance_sheet (quarterly, 2025-03-31) — Cash Financial: 4472000.00
LYPSAGEMS.NS cash_flow (annual, 2025-03-31) — Change In Inventory: -13714000.00
LYPSAGEMS.NS cash_flow (annual, 2025-03-31) — Change In Other Current Assets: 496000.00
LYPSAGEMS.NS cash_flow (annual, 2025-03-31) — Change In Other Current Liabilities: -48000.00
LYPSAGEMS.NS cash_flow (annual, 2025-03-31) — Change In Payable: -16294000.00
LYPSAGEMS.NS cash_flow (annual, 2025-03-31) — Change In Receivables: -40483000.00
LYPSAGEMS.NS cash_flow (annual, 2025-03-31) — Change In Working Capital: -70043000.00
LYPSAGEMS.NS cash_flow (annual, 2025-03-31) — Changes In Cash: 7000.00
LYPSAGEMS.NS balance_sheet (annual, 2025-03-31) — Common Stock: 294840000.00
LYPSAGEMS.NS balance_sheet (quarterly, 2025-03-31) — Common Stock: 294840000.00
LYPSAGEMS.NS balance_sheet (annual, 2025-03-31) — Common Stock Equity: 164907000.00
LYPSAGEMS.NS balance_sheet (quarterly, 2025-03-31) — Common Stock Equity: 164907000.00
LYPSAGEMS.NS balance_sheet (annual, 2025-03-31) — Construction In Progress: 0.00
LYPSAGEMS.NS balance_sheet (quarterly, 2025-03-31) — Construction In Progress: 0.00
LYPSAGEMS.NS income_statement (annual, 2025-03-31) — Cost Of Revenue: 162711000.00
LYPSAGEMS.NS income_statement (quarterly, 2025-03-31) — Cost Of Revenue: 65147000.00
LYPSAGEMS.NS balance_sheet (annual, 2025-03-31) — Current Assets: 627217000.00
LYPSAGEMS.NS balance_sheet (quarterly, 2025-03-31) — Current Assets: 627217000.00
LYPSAGEMS.NS balance_sheet (annual, 2025-03-31) — Current Debt: 129758000.00
LYPSAGEMS.NS balance_sheet (quarterly, 2025-03-31) — Current Debt: 129758000.00
LYPSAGEMS.NS balance_sheet (annual, 2025-03-31) — Current Debt And Capital Lease Obligation: 129758000.00
LYPSAGEMS.NS balance_sheet (quarterly, 2025-03-31) — Current Debt And Capital Lease Obligation: 129758000.00
LYPSAGEMS.NS balance_sheet (annual, 2025-03-31) — Current Deferred Assets: 0.00
LYPSAGEMS.NS balance_sheet (quarterly, 2025-03-31) — Current Deferred Assets: 0.00
LYPSAGEMS.NS balance_sheet (annual, 2025-03-31) — Current Liabilities: 486837000.00
LYPSAGEMS.NS balance_sheet (quarterly, 2025-03-31) — Current Liabilities: 486837000.00
LYPSAGEMS.NS balance_sheet (annual, 2025-03-31) — Current Provisions: 366000.00
LYPSAGEMS.NS balance_sheet (quarterly, 2025-03-31) — Current Provisions: 366000.00
LYPSAGEMS.NS cash_flow (annual, 2025-03-31) — Deferred Tax: 185000.00
LYPSAGEMS.NS cash_flow (annual, 2025-03-31) — Depreciation: 2146000.00
LYPSAGEMS.NS cash_flow (annual, 2025-03-31) — Depreciation And Amortization: 2146000.00
LYPSAGEMS.NS income_statement (annual, 2025-03-31) — Depreciation And Amortization In Income Statement: 2146000.00
LYPSAGEMS.NS income_statement (quarterly, 2025-03-31) — Depreciation And Amortization In Income Statement: 520000.00
LYPSAGEMS.NS income_statement (annual, 2025-03-31) — Depreciation Income Statement: 2146000.00
LYPSAGEMS.NS income_statement (quarterly, 2025-03-31) — Depreciation Income Statement: 520000.00
LYPSAGEMS.NS income_statement (annual, 2025-03-31) — Diluted Average Shares: 29465437.00
LYPSAGEMS.NS income_statement (quarterly, 2025-03-31) — Diluted Average Shares: 29494402.00
LYPSAGEMS.NS income_statement (annual, 2025-03-31) — Diluted EPS: -5.15
LYPSAGEMS.NS income_statement (quarterly, 2025-03-31) — Diluted EPS: -5.18
LYPSAGEMS.NS income_statement (annual, 2025-03-31) — Diluted NI Availto Com Stockholders: -151747000.00
LYPSAGEMS.NS income_statement (quarterly, 2025-03-31) — Diluted NI Availto Com Stockholders: -152781000.00
LYPSAGEMS.NS balance_sheet (annual, 2025-03-31) — Dividends Payable: 4336000.00
LYPSAGEMS.NS balance_sheet (quarterly, 2025-03-31) — Dividends Payable: 4336000.00
LYPSAGEMS.NS income_statement (annual, 2025-03-31) — EBIT: -151932000.00
LYPSAGEMS.NS income_statement (quarterly, 2025-03-31) — EBIT: -152966000.00
LYPSAGEMS.NS income_statement (annual, 2025-03-31) — EBITDA: -149786000.00
LYPSAGEMS.NS income_statement (quarterly, 2025-03-31) — EBITDA: -152446000.00
LYPSAGEMS.NS cash_flow (annual, 2025-03-31) — End Cash Position: 4472000.00
LYPSAGEMS.NS cash_flow (annual, 2025-03-31) — Financing Cash Flow: 68400000.00
LYPSAGEMS.NS balance_sheet (annual, 2025-03-31) — Finished Goods: 18566000.00
LYPSAGEMS.NS balance_sheet (quarterly, 2025-03-31) — Finished Goods: 18566000.00
LYPSAGEMS.NS cash_flow (annual, 2025-03-31) — Free Cash Flow: -68393000.00
LYPSAGEMS.NS cash_flow (annual, 2025-03-31) — Gain Loss On Sale Of PPE: 0.00
LYPSAGEMS.NS income_statement (annual, 2025-03-31) — General And Administrative Expense: 1247000.00
LYPSAGEMS.NS balance_sheet (annual, 2025-03-31) — Goodwill And Other Intangible Assets: 0.00
LYPSAGEMS.NS balance_sheet (quarterly, 2025-03-31) — Goodwill And Other Intangible Assets: 0.00
LYPSAGEMS.NS balance_sheet (annual, 2025-03-31) — Gross PPE: 65872000.00
LYPSAGEMS.NS balance_sheet (quarterly, 2025-03-31) — Gross PPE: 65872000.00
LYPSAGEMS.NS income_statement (annual, 2025-03-31) — Gross Profit: 4165000.00
LYPSAGEMS.NS income_statement (quarterly, 2025-03-31) — Gross Profit: 627000.00
LYPSAGEMS.NS income_statement (annual, 2025-03-31) — Interest Expense: 0.00
LYPSAGEMS.NS income_statement (quarterly, 2025-03-31) — Interest Expense: 0.00
LYPSAGEMS.NS income_statement (annual, 2025-03-31) — Interest Expense Non Operating: 0.00
LYPSAGEMS.NS income_statement (quarterly, 2025-03-31) — Interest Expense Non Operating: 0.00
LYPSAGEMS.NS income_statement (annual, 2025-03-31) — Interest Income: 0.00
LYPSAGEMS.NS income_statement (annual, 2025-03-31) — Interest Income Non Operating: 0.00
LYPSAGEMS.NS balance_sheet (annual, 2025-03-31) — Inventory: 22267000.00
LYPSAGEMS.NS balance_sheet (quarterly, 2025-03-31) — Inventory: 22267000.00
LYPSAGEMS.NS balance_sheet (annual, 2025-03-31) — Invested Capital: 294665000.00
LYPSAGEMS.NS balance_sheet (quarterly, 2025-03-31) — Invested Capital: 294665000.00
LYPSAGEMS.NS cash_flow (annual, 2025-03-31) — Investing Cash Flow: 0.00
LYPSAGEMS.NS balance_sheet (annual, 2025-03-31) — Investmentin Financial Assets: 0.00
LYPSAGEMS.NS balance_sheet (quarterly, 2025-03-31) — Investmentin Financial Assets: 0.00
LYPSAGEMS.NS cash_flow (annual, 2025-03-31) — Issuance Of Debt: 68400000.00
LYPSAGEMS.NS balance_sheet (annual, 2025-03-31) — Land And Improvements: 5720000.00
LYPSAGEMS.NS balance_sheet (quarterly, 2025-03-31) — Land And Improvements: 5720000.00
LYPSAGEMS.NS balance_sheet (annual, 2025-03-31) — Machinery Furniture Equipment: 44354000.00
LYPSAGEMS.NS balance_sheet (quarterly, 2025-03-31) — Machinery Furniture Equipment: 44354000.00
LYPSAGEMS.NS balance_sheet (annual, 2025-03-31) — Net Debt: 125286000.00
LYPSAGEMS.NS balance_sheet (quarterly, 2025-03-31) — Net Debt: 125286000.00
LYPSAGEMS.NS income_statement (annual, 2025-03-31) — Net Income: -151747000.00
LYPSAGEMS.NS income_statement (quarterly, 2025-03-31) — Net Income: -152781000.00
LYPSAGEMS.NS income_statement (annual, 2025-03-31) — Net Income Common Stockholders: -151747000.00
LYPSAGEMS.NS income_statement (quarterly, 2025-03-31) — Net Income Common Stockholders: -152781000.00
LYPSAGEMS.NS income_statement (annual, 2025-03-31) — Net Income Continuous Operations: -151747000.00
LYPSAGEMS.NS income_statement (quarterly, 2025-03-31) — Net Income Continuous Operations: -152781000.00
LYPSAGEMS.NS income_statement (annual, 2025-03-31) — Net Income From Continuing And Discontinued Operation: -151747000.00
LYPSAGEMS.NS income_statement (quarterly, 2025-03-31) — Net Income From Continuing And Discontinued Operation: -152781000.00
LYPSAGEMS.NS income_statement (annual, 2025-03-31) — Net Income From Continuing Operation Net Minority Interest: -151747000.00
LYPSAGEMS.NS income_statement (quarterly, 2025-03-31) — Net Income From Continuing Operation Net Minority Interest: -152781000.00
LYPSAGEMS.NS cash_flow (annual, 2025-03-31) — Net Income From Continuing Operations: -151932000.00
LYPSAGEMS.NS income_statement (annual, 2025-03-31) — Net Income Including Noncontrolling Interests: -151747000.00
LYPSAGEMS.NS income_statement (quarterly, 2025-03-31) — Net Income Including Noncontrolling Interests: -152781000.00
LYPSAGEMS.NS income_statement (annual, 2025-03-31) — Net Interest Income: 0.00
LYPSAGEMS.NS income_statement (quarterly, 2025-03-31) — Net Interest Income: 0.00
LYPSAGEMS.NS cash_flow (annual, 2025-03-31) — Net Issuance Payments Of Debt: 68400000.00
LYPSAGEMS.NS income_statement (annual, 2025-03-31) — Net Non Operating Interest Income Expense: 0.00
LYPSAGEMS.NS income_statement (quarterly, 2025-03-31) — Net Non Operating Interest Income Expense: 0.00
LYPSAGEMS.NS balance_sheet (annual, 2025-03-31) — Net PPE: 26959000.00
LYPSAGEMS.NS balance_sheet (quarterly, 2025-03-31) — Net PPE: 26959000.00
LYPSAGEMS.NS cash_flow (annual, 2025-03-31) — Net PPE Purchase And Sale: 0.00
LYPSAGEMS.NS cash_flow (annual, 2025-03-31) — Net Short Term Debt Issuance: 68400000.00
LYPSAGEMS.NS balance_sheet (annual, 2025-03-31) — Net Tangible Assets: 164907000.00
LYPSAGEMS.NS balance_sheet (quarterly, 2025-03-31) — Net Tangible Assets: 164907000.00
LYPSAGEMS.NS balance_sheet (annual, 2025-03-31) — Non Current Deferred Taxes Assets: 0.00
LYPSAGEMS.NS balance_sheet (quarterly, 2025-03-31) — Non Current Deferred Taxes Assets: 0.00
LYPSAGEMS.NS balance_sheet (annual, 2025-03-31) — Non Current Deferred Taxes Liabilities: 3201000.00
LYPSAGEMS.NS balance_sheet (quarterly, 2025-03-31) — Non Current Deferred Taxes Liabilities: 3201000.00
LYPSAGEMS.NS balance_sheet (annual, 2025-03-31) — Non Current Prepaid Assets: 42000.00
LYPSAGEMS.NS balance_sheet (quarterly, 2025-03-31) — Non Current Prepaid Assets: 42000.00
LYPSAGEMS.NS income_statement (annual, 2025-03-31) — Normalized EBITDA: -149786000.00
LYPSAGEMS.NS income_statement (quarterly, 2025-03-31) — Normalized EBITDA: -152446000.00
LYPSAGEMS.NS income_statement (annual, 2025-03-31) — Normalized Income: -151747000.00
LYPSAGEMS.NS income_statement (quarterly, 2025-03-31) — Normalized Income: -152781000.00
LYPSAGEMS.NS cash_flow (annual, 2025-03-31) — Operating Cash Flow: -68393000.00
LYPSAGEMS.NS income_statement (annual, 2025-03-31) — Operating Income: -151932000.00
LYPSAGEMS.NS income_statement (quarterly, 2025-03-31) — Operating Income: -152966000.00
LYPSAGEMS.NS income_statement (annual, 2025-03-31) — Operating Revenue: 166876000.00
LYPSAGEMS.NS income_statement (quarterly, 2025-03-31) — Operating Revenue: 65774000.00
LYPSAGEMS.NS balance_sheet (annual, 2025-03-31) — Ordinary Shares Number: 29484000.00
LYPSAGEMS.NS balance_sheet (quarterly, 2025-03-31) — Ordinary Shares Number: 29484000.00
LYPSAGEMS.NS balance_sheet (annual, 2025-03-31) — Other Current Assets: 768000.00
LYPSAGEMS.NS balance_sheet (quarterly, 2025-03-31) — Other Current Assets: 768000.00
LYPSAGEMS.NS balance_sheet (annual, 2025-03-31) — Other Current Liabilities: 3000.00
LYPSAGEMS.NS balance_sheet (quarterly, 2025-03-31) — Other Current Liabilities: 3000.00
LYPSAGEMS.NS balance_sheet (annual, 2025-03-31) — Other Equity Interest: -129933000.00
LYPSAGEMS.NS balance_sheet (quarterly, 2025-03-31) — Other Equity Interest: -129933000.00
LYPSAGEMS.NS cash_flow (annual, 2025-03-31) — Other Non Cash Items: -400000.00
LYPSAGEMS.NS income_statement (annual, 2025-03-31) — Other Operating Expenses: 153783000.00
LYPSAGEMS.NS income_statement (quarterly, 2025-03-31) — Other Operating Expenses: 153031000.00
LYPSAGEMS.NS balance_sheet (annual, 2025-03-31) — Other Payable: 371000.00
LYPSAGEMS.NS balance_sheet (quarterly, 2025-03-31) — Other Payable: 371000.00
LYPSAGEMS.NS balance_sheet (annual, 2025-03-31) — Other Properties: 1086000.00
LYPSAGEMS.NS balance_sheet (quarterly, 2025-03-31) — Other Properties: 1086000.00
LYPSAGEMS.NS balance_sheet (annual, 2025-03-31) — Other Short Term Investments: 4448000.00
LYPSAGEMS.NS balance_sheet (quarterly, 2025-03-31) — Other Short Term Investments: 4448000.00